RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

Status Withdrawn

Clinical Trial Summary

Clinical Trial Description

The purpose of this research study is to determine the rate of local regional control at 2 years when using de-intensified chemoradiotherapy (CRT) in patients with Human Papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC). Local regional control means no recurrence of the cancer in the head or neck area. Study subjects will be enrolled into 4 groups. Group/treatment will be based on a number of factors, including smoking and drinking history. If participants choose to participate, participants will be asked to: - Participate in screening for eligibility, this will include: questions regarding \medical history, physical exam, blood/urine samples, electrocardiogram, PET/CT and/or CT-MRI of the neck, assessment of tumor, and a questionnaire. - Complete the study regimen including evaluations and follow up visits. Participants may be in this research study for approximately to 5 years after receiving standard of care (SOC) treatment. Depending on the group enrolled in, the treatment will last either 6 weeks (Groups 1-3) or 15 weeks (Group 4.This group will also receive 3 cycles of SOC induction therapy (One cycle = 21 days). Induction therapy is initial chemotherapy delivered prior to radiation or surgery when treating cancer. - Participate in routine types of procedures such as clinical exams, blood and urine tests, and imaging tests to assess tumor. - Consent to storage of research samples. This research study involves chemotherapy and intensity-modulated radiation therapy (IMRT) IMRT is used to safely deliver precise radiation to a tumor while minimizing the dose to surrounding normal tissue. There are no added costs associated with participation. There is no reimbursement for participation. The names of the drugs/interventions involved in this study are: - Cisplatin - Docetaxel (Group 4 only) - Fluorouracil (Group 4 only) - Carboplatin (Group 4 Only) All of the drugs listed above are approved for use by the Food and Drug Administration (FDA), commercially available, and considered standard of care (SOC) for cancer. Serious known side effects that participants may experience include: - Nausea and vomiting - Diarrhea - Fever - Skin irritation, rash - Joint pain ;

Study Design

Related Conditions & MeSH terms

Head and Neck Squamous Cell Carcinoma (HNSCC)
Human Papillomavirus (HPV)
Squamous Cell Carcinoma of Head and Neck

Clinical Trial Details

NCT number	NCT04849377
Study type	Interventional
Source	Icahn School of Medicine at Mount Sinai
Contact
Status	Withdrawn
Phase	Phase 2
Start date	June 14, 2022
Completion date	June 14, 2022

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02211027` - Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA	Phase 1
Recruiting	`NCT04083599` - GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors	Phase 1/Phase 2
Completed	`NCT03735628` - An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05891171` - Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers	Phase 1
Recruiting	`NCT03546582` - SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma	Phase 2
Not yet recruiting	`NCT06102447` - Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma	N/A
Not yet recruiting	`NCT06295731` - INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC	Phase 2/Phase 3
Terminated	`NCT00911326` - Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma	Phase 3
Completed	`NCT04220866` - Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)	Phase 2
Withdrawn	`NCT03114280` - Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	Phase 1/Phase 2
Completed	`NCT02764593` - Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer	Phase 1
Completed	`NCT03268993` - Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer	N/A
Recruiting	`NCT04284540` - Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma	N/A
Recruiting	`NCT04080804` - Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer	Phase 2
Active, not recruiting	`NCT04215978` - Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT03746431` - A Phase 1/2 Study of [225Ac]-FPI-1434 Injection	Phase 1/Phase 2
Active, not recruiting	`NCT05249426` - A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer	Phase 1
Not yet recruiting	`NCT05473156` - A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies	Phase 1/Phase 2
Completed	`NCT02684253` - Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	Phase 2
Terminated	`NCT03276819` - A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML or HNSCC	N/A